专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009027626A3 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物的改进或与有机化合物有关的改进
公开(公告)号：WO2009027626A3
公开(公告)日：2009-12-10
申请号：PCT/GB2008002738
申请日：2008-08-12
申请人： SYNGENTA LTD , BELL GORDON ALASTAIR , HARRIS CLAIR LOUISE , TOVEY IAN DAVID
发明人： BELL GORDON ALASTAIR , HARRIS CLAIR LOUISE , TOVEY IAN DAVID
IPC分类号： A01N25/02
CPC分类号： A01N25/02 , A01N37/36 , A01N37/42 , A01N43/90 , A01N2300/00
摘要： A composition comprising a compound of formula I CH3CH(OH)CC=O)NR1R2 (I) where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl; and at least one agrochemical selected from the group consisting of Trinexepac ethyl, Mandipropamid, Abamectin and Emamectin, with the proviso that the agrochemical is not abamectin or emamectin when the solvent is N-(B-hydroxyethyl)- lactamide. Such compositions may be, or may be comprised by, emulsion concentrates.
摘要翻译：包含式I化合物的组合物，其中R 1和R 2各自独立地为氢; 或C 1-6烷基，C 2-6烯基或C 3-6环烷基，其各自任选被至多三个独立选自苯基，羟基，C 1-5烷氧基，吗啉基和NR 3 R 4的取代基取代，其中R 3和R 4各自独立地为C 1 -3烷基; 或苯基，其任选被至多三个独立地选自C 1-3烷基的取代基取代; 或者R 1和R 2与它们所连接的氮原子一起形成吗啉基，吡咯烷基，哌啶基或氮杂环庚烷基环，其各自任选被至多三个取代基取代，所述取代基独立地选自C 1-3烷基; 和至少一种选自由Trinexepac乙基，Mandipropamid，阿维菌素和Emamectin组成的组的农业化学品，条件是当溶剂为N-（B-羟乙基） - 乳酰胺时农药不是阿维菌素或emamectin。这种组合物可以是或可以由乳液浓缩物构成。

2. 发明申请

WO2009027626A2 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物的改善或有关
公开(公告)号：WO2009027626A2
公开(公告)日：2009-03-05
申请号：PCT/GB2008/002738
申请日：2008-08-12
申请人： SYNGENTA LIMITED , BELL, Gordon, Alastair , HARRIS, Clair, Louise , TOVEY, Ian, David
发明人： BELL, Gordon, Alastair , HARRIS, Clair, Louise , TOVEY, Ian, David
IPC分类号： A01N25/02 , A01N37/36 , A01N43/90 , A01N37/42 , A01P3/00 , A01P7/00
CPC分类号： A01N25/02 , A01N37/36 , A01N37/42 , A01N43/90 , A01N2300/00
摘要： A composition comprising a compound of formula I CH 3 CH(OH)CC=O)NR 1 R 2 (I) where R 1 and R 2 are each independently hydrogen; or C 1-6 alkyl, C 2-6 alkenyl or C 3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C 1-5 alkoxy, morpholinyl and NR 3 R 4 where R 3 and R 4 are each independently C 1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C 1-3 alkyl; or R 1 and R 2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C 1-3 alkyl; and at least one agrochemical selected from the group consisting of Trinexepac ethyl, Mandipropamid, Abamectin and Emamectin, with the proviso that the agrochemical is not abamectin or emamectin when the solvent is N-(B-hydroxyethyl)- lactamide. Such compositions may be, or may be comprised by, emulsion concentrates.
摘要翻译：包含式I的化合物CH 3 CH（OH）C C = O）NR 1 R 2（I）的组合物，其中R 1和R 2各自独立地为氢; 或C 1-6烷基，C 2-6烯基或C 3-6环烷基，其各自任选被至多三个独立地选自苯基，羟基，C 1-5烷氧基，吗啉基和NR 3 R 4的取代基取代，其中R 3和R 4各自独立地为C 1 -3烷基; 或任选被至多三个独立地选自C 1-3烷基的取代基取代的苯基; 或R 1和R 2与它们所连接的氮原子一起形成吗啉基，吡咯烷基，哌啶基或氮杂环庚烷环，其各自任选被至多三个独立地选自C 1-3烷基的取代基取代; 和选自Trinexepac乙基，Mandipropamid，阿维菌素和Emamectin的至少一种农药，条件是当溶剂是N-（B-羟乙基） - 乳酰胺时，农药不是阿维菌素或阿维菌素。这样的组合物可以是或可以由乳液浓缩物组成。

3. 发明申请

WO2008090332A3 FACTOR H POLYMORPHISMS IN THE DIAGNOSIS AND THERAPY OF INFLAMMATORY DISEASES SUCH AS AGE-RELATED MACULAR DEGENERATION 审中-公开
标题翻译： F因子H多态性在诊断和治疗炎性疾病如年龄相关性黄斑变性
公开(公告)号：WO2008090332A3
公开(公告)日：2008-10-23
申请号：PCT/GB2008000218
申请日：2008-01-23
申请人： UNIV CARDIFF , MORGAN BRYAN PAUL , HARRIS CLAIR LOUISE , HAKOBYAN SVETLANA
发明人： MORGAN BRYAN PAUL , HARRIS CLAIR LOUISE , HAKOBYAN SVETLANA
IPC分类号： C07K14/47 , G01N33/68
CPC分类号： G01N33/564 , C07K16/18 , G01N2333/4716 , G01N2800/164
摘要： The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.
摘要翻译：本发明涉及区分补体因子H的组氨酸和酪氨酸同种型的抗体，包括单克隆和多克隆或其片段，并涉及它们在与补体因子H介导的疾病相关的诊断方法和治疗性治疗中的用途。

4. 发明申请

WO2008090332A2 FACTOR H POLYMORPHISMS IN THE DIAGNOSIS AND THERAPY OF INFLAMMATORY DISEASES SUCH AS AGE-RELATED MACULAR DEGENERATION 审中-公开
标题翻译：因素H多态性在诊断和治疗炎症性疾病如年龄相关性变性
公开(公告)号：WO2008090332A2
公开(公告)日：2008-07-31
申请号：PCT/GB2008/000218
申请日：2008-01-23
申请人： UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED , MORGAN, Bryan, Paul , HARRIS, Clair, Louise , HAKOBYAN, Svetlana
发明人： MORGAN, Bryan, Paul , HARRIS, Clair, Louise , HAKOBYAN, Svetlana
IPC分类号： G01N33/50
CPC分类号： G01N33/564 , C07K16/18 , G01N2333/4716 , G01N2800/164
摘要： The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.
摘要翻译：本发明涉及区分补体因子H的组氨酸和酪氨酸同种型的单克隆和多克隆或其片段的抗体及其在与补体因子H介导的疾病相关的诊断方法和治疗性治疗中的用途。

5. 发明申请

WO2009027624A3 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物的改善或有关
公开(公告)号：WO2009027624A3
公开(公告)日：2009-12-10
申请号：PCT/GB2008002730
申请日：2008-08-13
申请人： SYNGENTA LTD , BELL GORDON ALASTAIR , HARRIS CLAIR LOUISE , TOVEY IAN DAVID
发明人： BELL GORDON ALASTAIR , HARRIS CLAIR LOUISE , TOVEY IAN DAVID
IPC分类号： A01N25/02
CPC分类号： A01N25/02 , A01N35/10 , A01N37/34 , A01N39/02 , A01N43/36 , A01N43/54 , A01N43/56 , A01N43/653 , A01N43/70 , A01N43/90 , A01N45/02 , A01N47/30 , A01N51/00 , A01N2300/00
摘要： A composition comprising a compound of formula (I) CH3CH(OH)C(=O)NR1R2 where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl; and at least one biologically active compound, which comprises at least one aromatic five and/or six tnembered ring wherein the ring contains at least one nitrogen as a ring member, with the provisos (i) that the composition does not contain cyproconazole when the compound of formula (1) is selected from the group consisting of N-butoxypropyl lactamide; 1-(hydroxyethyl) piperidinyl lactamide; N-methyl-N-propyl lactamide; N-(1-ethylpropyl) lactamide; N,N-dimethyl lactamide; N-1,4-dimethylpentyl lactamide; N-(2-hydroxyethyl)-N-benzyl lactamide; N-Morpholinyl lactamide; N-methyl-N-butyl lactamide; N-Isobutyl lactamide; N-AlIyI lactamide; N-Ethyl lactamide; N-Ethyl-N-(2-hydroxyethyl) lactamide; and N-isopropyl lactamide; and (ii) that the biologically active compound is not nicotinic acid when the compound of formula (1) is diethyl-lactamide. Such compositions may be, or may be comprised by, emulsion concentrates, particularly so in the case that the compound of formula (I) is dimethyl lactamide and the biologically active compound is the fungicide 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid(9-isopropyl-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide shown in Figure 2.
摘要翻译：一种组合物，其包含式（I）化合物：CH 3 CH（OH）C（= O）NR 1 R 2，其中R 1和R 2各自独立地为氢; 或C 1-6烷基，C 2-6烯基或C 3-6环烷基，其各自任选被至多三个独立地选自苯基，羟基，C 1-5烷氧基，吗啉基和NR 3 R 4的取代基取代，其中R 3和R 4各自独立地为C 1 -3烷基; 或任选被至多三个独立地选自C 1-3烷基的取代基取代的苯基; 或R 1和R 2与它们所连接的氮原子一起形成吗啉基，吡咯烷基，哌啶基或氮杂环庚烷环，其各自任选被至多三个独立地选自C 1-3烷基的取代基取代; 和至少一种生物活性化合物，其包含至少一个芳族五和/或六个记录环，其中所述环含有至少一个氮作为环成员，条件是（i）当化合物不含有环丙唑啉时式（1）的化合物选自N-丁氧基丙基乳酰胺; 1-（羟乙基）哌啶基酰胺; N-甲基-N-丙基乳酰胺; N-（1-乙基丙基）乳酰胺; N，N-二甲基乳酰胺; N-1,4-二甲基戊酰基乳酰胺; N-（2-羟乙基）-N-苄基乳酰胺; N-吗啉基乳酰胺; N-甲基-N-丁基乳酰胺; N-异丁基乳酰胺; N-酰胺酰胺; N-乙基乳酰胺; N-乙基-N-（2-羟乙基）乳酰胺; 和N-异丙基乳酰胺; 和（ii）当式（1）的化合物是二乙基 - 乳酰胺时，生物活性化合物不是烟酸。这样的组合物可以是或可以由乳液浓缩物组成，特别是在式（I）化合物是二甲基乳酰胺并且生物活性化合物是杀真菌剂3-二氟甲基-1-甲基-1H-吡唑-2-基）（9-异丙基-1,2,3,4-四氢-1,4-亚甲基 - 萘-5-基） - 酰胺，如图2所示。

6. 发明申请

WO2009027624A2 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物的改进或与有机化合物有关的改进
公开(公告)号：WO2009027624A2
公开(公告)日：2009-03-05
申请号：PCT/GB2008/002730
申请日：2008-08-13
申请人： SYNGENTA LIMITED , BELL, Gordon, Alastair , HARRIS, Clair, Louise , TOVEY, Ian, David
发明人： BELL, Gordon, Alastair , HARRIS, Clair, Louise , TOVEY, Ian, David
IPC分类号： A01N25/02 , A01N43/90 , A01N45/02 , A01N43/56 , A01N43/36 , A01N47/30 , A01N43/653 , A01N43/70 , A01N51/00 , A01N43/54 , A01N37/34 , A01N35/10 , A01N39/02 , A01P3/00 , A01P7/04
CPC分类号： A01N25/02 , A01N35/10 , A01N37/34 , A01N39/02 , A01N43/36 , A01N43/54 , A01N43/56 , A01N43/653 , A01N43/70 , A01N43/90 , A01N45/02 , A01N47/30 , A01N51/00 , A01N2300/00
摘要： A composition comprising a compound of formula (I) CH 3 CH(OH)C(=O)NR 1 R 2 where R 1 and R 2 are each independently hydrogen; or C 1-6 alkyl, C 2-6 alkenyl or C 3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C 1-5 alkoxy, morpholinyl and NR 3 R 4 where R 3 and R 4 are each independently C 1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C 1-3 alkyl; or R 1 and R 2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C 1-3 alkyl; and at least one biologically active compound, which comprises at least one aromatic five and/or six tnembered ring wherein the ring contains at least one nitrogen as a ring member, with the provisos (i) that the composition does not contain cyproconazole when the compound of formula (1) is selected from the group consisting of N-butoxypropyl lactamide; 1-(hydroxyethyl) piperidinyl lactamide; N-methyl-N-propyl lactamide; N-(1-ethylpropyl) lactamide; N,N-dimethyl lactamide; N-1,4-dimethylpentyl lactamide; N-(2-hydroxyethyl)-N-benzyl lactamide; N-Morpholinyl lactamide; N-methyl-N-butyl lactamide; N-Isobutyl lactamide; N-AlIyI lactamide; N-Ethyl lactamide; N-Ethyl-N-(2-hydroxyethyl) lactamide; and N-isopropyl lactamide; and (ii) that the biologically active compound is not nicotinic acid when the compound of formula (1) is diethyl-lactamide. Such compositions may be, or may be comprised by, emulsion concentrates, particularly so in the case that the compound of formula (I) is dimethyl lactamide and the biologically active compound is the fungicide 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid(9-isopropyl-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide shown in Figure 2.
摘要翻译：包含式（I）CH 3 CH（OH）C（= O）NR 1 R 2 2化合物的组合物其中R 1和R 2各自独立地为氢; 或C 1-6烷基，C 2-6烯基或C 3-6环烷基，其各自任选被至多三个独立地选自苯基，羟基，C 1-5烷氧基，吗啉基和NR 3 R 4的取代基，其中R 3为 R 4和R 4各自独立地为C 1-3烷基; 或苯基，其任选被至多三个取代基取代，所述取代基独立地选自C 1-3烷基; 或者R 1和R 2与它们所连接的氮原子一起形成吗啉基，吡咯烷基，哌啶基或氮杂环庚烷基环，其各自任选被至多1个三个独立选自C 1-3烷基的取代基; 和至少一种生物活性化合物，所述生物活性化合物包含至少一个芳族五和/或六元环，其中所述环含有至少一个氮作为环成员，条件是（i）组合物当式（1）化合物选自N-丁氧基丙基乳酰胺; 1-（羟乙基）哌啶基乳酰胺; N-甲基-N-丙基乳酰胺; N-（1-乙基丙基）乳酰胺; N，N-二甲基乳酰胺; N-1,4-二甲基戊基乳酰胺; N-（2-羟乙基）-N-苄基乳酰胺; N-吗啉基乳酰胺; N-甲基-N-丁基乳酰胺; N-异丁基乳酰胺; N-烯丙基乳酰胺; N-乙基乳酰胺; N-乙基-N-（2-羟乙基）乳酰胺; 和N-异丙基乳酰胺; 和（ii）当式（1）化合物是二乙基 - 乳酰胺时，生物活性化合物不是烟酸。这样的组合物可以是乳剂浓缩物或者可以由乳剂浓缩物组成，特别是在式（I）化合物是二甲基乳酰胺并且生物活性化合物是杀真菌剂3-二氟甲基-1-甲基-1H-吡唑-3-甲酰胺（9-异丙基-1,2,3,4-四氢-1,4-亚甲基 - 萘-5-基） - 酰胺（图2）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式